ReviewJournal of cellular physiology2019
Modulation of the immune response by Middle East respiratory syndrome coronavirus.
Review in Journal of cellular physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 97 citations in OpenAlex.
- Risk Prediction of Coronary Artery Stenosis in Patients with Coronary Heart Disease Based on Logistic Regression and Artificial Neural Network.Computational and mathematical methods in medicine · 2022Trial
- Association of KIR Genes with Middle East Respiratory Syndrome Coronavirus Infection in South Koreans.Journal of clinical medicine · 2024Article
- Mucosal immunity in upper and lower respiratory tract to MERS-CoV.Frontiers in immunology · 2024Review
- Middle East Respiratory Syndrome Coronavirus Could be a Priority Pathogen to Cause Public Health Emergency: Noticeable Features and Counteractive Measures.Environmental health insights · 2024Article
- COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte.Journal of infection and public health · 2023Review
- Functionality of immune cells in COVID-19 infection: development of cell-based therapeutics.BioImpacts : BI · 2023Review
- Article
- Two Years into the COVID-19 Pandemic: Lessons Learned.ACS infectious diseases · 2022Review
- Opportunities and Challenges in Targeting the Proofreading Activity of SARS-CoV-2 Polymerase Complex.Molecules (Basel, Switzerland) · 2022Review
- Yoga, immunity and COVID-19: A scoping review.Journal of family medicine and primary care · 2022Article
- Long noncoding RNAs in respiratory viruses: A review.Reviews in medical virology · 2022Review
- Insights into the evolutionary and prophylactic analysis of SARS-CoV-2: A review.Journal of virological methods · 2022Review
- Liposome-Mediated Delivery of MERS Antigen Induces Potent Humoral and Cell-Mediated Immune Response in Mice.Molecules (Basel, Switzerland) · 2022Article
- Positive correlation between VCA-IgM and Th1/Th2 immunocytokines in children with infectious mononucleosis.American journal of translational research · 2022Article
- Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Review
- COVID-19 and the differences in physiological background between children and adults and their clinical consequences.Physiological research · 2021Review
- Molecular Insights into the Crosstalk Between Immune Inflammation Nexus and SARS-CoV-2 Virus.Current microbiology · 2021Review
- Mast cells: Therapeutic targets for COVID-19 and beyond.IUBMB life · 2021Review
- Interactions between SARS coronavirus 2 papain-like protease and immune system: A potential drug target for the treatment of COVID-19.Scandinavian journal of immunology · 2021Review
- Potential SARS-CoV-2 vaccines: Concept, progress, and challenges.International immunopharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus (CoV) infections are commonly associated with respiratory and enteric disease in humans and animals. In 2012, a new human disease called Middle East respiratory syndrome (MERS) emerged in the Middle East. MERS was caused by a virus that was originally called human coronavirus-Erasmus Medical Center/2012 but was later renamed as Middle East respiratory syndrome coronavirus (MERS-CoV). MERS-CoV causes high fever, cough, acute respiratory tract infection, and multiorgan dysfunction that may eventually lead to the death of the infected individuals. The exact origin of MERS-CoV remains unknown, but the transmission pattern and evidence from virological studies suggest that dromedary camels are the major reservoir host, from which human infections may sporadically occur through the zoonotic transmission. Human to human transmission also occurs in healthcare facilities and communities. Recent studies on Middle Eastern respiratory continue to highlight the need for further understanding the virus-host interactions that govern disease severity and infection outcome. In this review, we have highlighted the major mechanisms of immune evasion strategies of MERS-CoV. We have demonstrated that M, 4a, 4b proteins and Plppro of MERS-CoV inhibit the type I interferon (IFN) and nuclear factor-κB signaling pathways and therefore facilitate innate immune evasion. In addition, nonstructural protein 4a (NSP4a), NSP4b, and NSP15 inhibit double-stranded RNA sensors. Therefore, the mentioned proteins limit early induction of IFN and cause rapid apoptosis of macrophages. MERS-CoV strongly inhibits the activation of T cells with downregulation of antigen presentation. In addition, uncontrolled secretion of interferon ɣ-induced protein 10 and monocyte chemoattractant protein-1 can suppress proliferation of human myeloid progenitor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.